Sight Sciences, Inc. has announced that new data on the OMNI® Surgical System will be presented at the 2025 American Glaucoma Society Annual Meeting, showcasing significant clinical outcomes in real-world practice. A meta-analysis of 22 studies, along with data from the IRIS...
Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients' lives,...
The Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schle...
Announced the publication of a landmark 36-month analysis evaluating the long-term effectiveness of the OMNI®Surgical System in managing primary open-angle glaucoma. This study presented evidence supporting the sustained benefits of sta...
Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a MIGS technology indicated to reduce intraocular pressure in adult patients with ...
Sight Sciences (Nasdaq:SGHT) announced today that 36-month data supports the use of its Omni surgical system. Data from the three-year post-surgery follow-up demonstrates that the Omni surgical system delivers safe, consistent and durable results in adult patients with open-angle glaucoma (OAG)...
Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI®Surgical System is a minimally invasive glaucoma surgery (M...
Sight Sciences Inc is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. The company’s product portfolio features the OMNI Surgical System, a dually-indicated device that facilitates the perfo...
Sight Sciences Inc is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. The company’s product portfolio features the OMNI Surgical System, a dually-indicated device that facilitates the performance of both...
Sight Sciences Launches OMNI® Edge Surgical System to Enhance Glaucoma Treatment Apr 21, 2025•Quiver Quantitative Stocks Insider Purchase: EVP of $SGHT Buys 10,000 Shares Mar 13, 2025•Quiver Quantitative Biotech Sight Sciences Expects 2025 Revenue To Decline By 6% To 12% ...